Literature DB >> 6739116

Drug abuse in migraine patients.

M Langemark, J Olesen.   

Abstract

Records of all patients discharged with a diagnosis of migraine from 2 Danish neurological departments were examined to determine the incidence of drug abuse. These departments had fixed uptake areas with a population of approximately 500,000 during the 5 year study period (1-1-1976--31-12-1980). Patients were selected for detailed analysis if (1) they used morphinomimetic drugs once a month or more, (2) took 7 or more tablets of weak analgesics a day or (3) consumed more than 60 mg ergotamine a month. A total of 92 patients fulfilled these criteria, 27 only because of ergotamine overuse. Injections of morphinomimetic drugs were given once a week or more frequently to 32 patients. These patients also usually had an escalating consumption and were usually regarded as abusers by their doctors. During admission morphinomimetics were discontinued. None deteriorated, 1/3 remained unchanged whereas 2/3 improved. Thus 32 patients can be regarded as abusers of morphinomimetics which represents an annual incidence of 13 per million inhabitants. We caution against the use of morphinomimetics in migraine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6739116     DOI: 10.1016/0304-3959(84)90067-8

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  5 in total

Review 1.  A review of current drugs for migraine.

Authors:  J Olesen
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

Review 2.  Diagnosis and management of migraine.

Authors:  P J Goadsby; J Olesen
Journal:  BMJ       Date:  1996-05-18

3.  Analgesic headache.

Authors:  J Olesen
Journal:  BMJ       Date:  1995-02-25

4.  Opioids can be useful in the treatment of headache.

Authors:  Cinzia Finocchi; Erica Viani
Journal:  Neurol Sci       Date:  2013-05       Impact factor: 3.307

5.  Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis.

Authors:  Juliana H VanderPluym; Rashmi B Halker Singh; Meritxell Urtecho; Allison S Morrow; Tarek Nayfeh; Victor D Torres Roldan; Magdoleen H Farah; Bashar Hasan; Samer Saadi; Sahrish Shah; Rami Abd-Rabu; Lubna Daraz; Larry J Prokop; Mohammad Hassan Murad; Zhen Wang
Journal:  JAMA       Date:  2021-06-15       Impact factor: 56.272

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.